Holen Sie sich die Stockscreener-App
12.62
3.81%
-0.50
Handel nachbörslich:
12.69
0.07
+0.55%
Schlusskurs vom Vortag:
$13.12
Offen:
$13.07
24-Stunden-Volumen:
126.78K
Relative Volume:
2.34
Marktkapitalisierung:
$1.18B
Einnahmen:
$106.66M
Nettoeinkommen (Verlust:
$15.16M
KGV:
-
EPS:
-
Netto-Cashflow:
$6.37M
1W Leistung:
-24.88%
1M Leistung:
-10.24%
6M Leistung:
-11.38%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.54
$13.54
1-Wochen-Bereich:
$12.54
$19.00
52-Wochen-Spanne:
$8.26
$27.10
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Firmenname
Gyre Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GYRE | 12.62 | 1.18B | 106.66M | 15.16M | 6.37M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-29 | Fortgesetzt | Stephens | Overweight |
| 2021-02-10 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-21 | Eingeleitet | Raymond James | Outperform |
| 2019-01-04 | Eingeleitet | Oppenheimer | Outperform |
| 2018-02-12 | Bestätigt | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-12-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-06-06 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-06-30 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Gyre Therapeutics Inc Aktie (GYRE) Neueste Nachrichten
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Declines By 16.1% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 7.8%Here's Why - MarketBeat
Gyre Therapeutics Third Quarter 2024 Earnings: EPS: US$0.013 (vs US$0.68 loss in 3Q 2023) - Yahoo Finance
Gyre Therapeutics Reports Q3 2024 Financial Results and Strategic Updates - TipRanks
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - The Manila Times
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides - The Bakersfield Californian
Gyre Therapeutics Revenue Falls 20% as Phase 3 Trial Milestone Nears Critical Data | GYRE Stock News - StockTitan
VirTra Appoints Retired U.S. Army Lieutenant General Maria R. Gervais and Georgia POST Executive Director Mike Ayers to Board of Directors - The Manila Times
Gyre Therapeutics Announces Last Patient Completed Pivotal Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis - The Manila Times
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 3.8%What's Next? - MarketBeat
AQR Capital Management LLC Invests $778,000 in Mativ Holdings, Inc. (NYSE:MATV) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap UpStill a Buy? - MarketBeat
Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) market cap dropped US$51m last week; Public companies bore the brunt - Yahoo Finance
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Coronation Fund Managers Ltd. Buys 1,044 Shares of The Sherwin-Williams Company (NYSE:SHW) - Defense World
Eaton Vance California Municipal Income Trust (NYSE:CEV) Major Shareholder Sells $282,451.70 in Stock - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading 3.3% HigherHere's What Happened - MarketBeat
Gyre Therapeutics to Present at 8th Annual H.C. Wainwright MASH Investor Conference - The Manila Times
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Down 7.0% in August - MarketBeat
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday - Benzinga
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 4.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 6.6% - MarketBeat
Gyre Therapeutics Inc (GYRE) Stock Price & Chart | Trade Now - Capital.com
Gyre Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 8.9% - MarketBeat
Short Interest in Gyre Therapeutics, Inc. (NASDAQ:GYRE) Grows By 5.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading 4.1% Higher - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 6.6% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Sees Unusually-High Trading Volume - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Stock Quotes, Forecast and News Summary - Benzinga
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees Significant Growth in Short Interest - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.2% - MarketBeat
Vanguard Group Inc. Reduces Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE) - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Up to $10.40 - MarketBeat
GYRE Stock Earnings: Gyre Therapeutics Reported Results for Q2 2024 - InvestorPlace
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 3.9% - MarketBeat
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update - BioSpace
Sidoti Events, LLC's Virtual August Micro-Cap Conference - AccessWire
Gyre Therapeutics (NASDAQ:GYRE) Trading 6.7% Higher - MarketBeat
Gyre Therapeutics to Present at Sidoti Virtual Investor Conference - ForexTV.com
Gyre Therapeutics Welcomes Dr. Epstein to Leadership Team - TipRanks
Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors - StockTitan
Gyre Therapeutics (NASDAQ:GYRE) versus Insmed (NASDAQ:INSM) Critical Comparison - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 18.9% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 8.4% - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 4.9% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 67.9% in July - MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Shares Down 4.3% - Defense World
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.3% - MarketBeat
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Update - Defense World
Finanzdaten der Gyre Therapeutics Inc-Aktie (GYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):